1 Antiplatelet Trialists'Collaboration. Collaborative overview of randomised trials of anti platelet thera py-Ⅰ. Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of pa-tients. Br Med J, 1994,308:81
2 ISIS-2(Second International Study of Infarct Sur-vival)Collaborative Group. Randomised trial of intra-venous stre ptokinase, oral as pirin, toth, or neither a-mong 17187 cases of suspected acute myocardial infarc-tion:ISIS-2.Lancet, 1988, Ⅱ:349
3 Baigent C, Collins R, ISIS-2.4-year mortality follow-up of 17187 patients after fibrinolytic and an-tiplatelet therapy in suspected acute my ocardial infarction (Abstr).Cir, 1993,88:Ⅰ
4 Roux S, Christeller S, Ludin E. Effects of aspirin on coronary reocclusion and recurrent ischemia after throm-bolysis:a metaanalysis.J Am Coll Cardiol, 1992, 19:671
5 陈在嘉, 徐义枢, 于全俊, 等. 小剂量阿斯匹林心肌梗 塞二级预防临床试验. 中华心血管病杂志, 1991, 19(6): 339
6 Antiplatelet T rialists'Collaboration.Secondary pre-vention of vascular disease by prolonged antiplatelet treatment. Br Med J, 1988,296:320
7 Hass WK, Easton JD, Adams HP, et al. For the Ticlopidine As pirin Stroke Study Group:A randomized trial comparing ticlopidinehy drochloride with as pirin for the prevention of stroke in high-risk patients. NEngl J Med, 1989,321:501
8 RAPT Investigators. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and throm-boxane A2/prostag landinendo peroxide receptor antago-nist, versus as pirin as adjunct to thrombolysis in patients with acute myocardial infarction.Cir, 1994,89:588
9 The EPIC Investigators.Use of a monoclonal anti-body directed against the platelet glycoprotein Ⅱ b/ Ⅲ a receptor in highrisk coronary angioplasty. NEngl J Med, 1994,330:956
10 Smith P, Arnesen H, Holme I. The effect of war-farin on mortality and reinfarction after myocardial in-farction. NEngl J Med. 1990, 323:147
11 Anticoa gulants in the Secondary Prevention of Events in Coronary Thrombosis (ASPECR)Research Group. Effect of long-termoral anticoa gulant treatment on mortality and cardiovascular morbidity after myocar-dial infarction.Lancet, 1994, 343:499
12 Almony G T, Lefkovits J, Topeol EJ. Antiplatelet and anticoagulant use after my ocardial infarction. Clin Cardiol, 1996,19:357
13 Glick A, Kornowski R, Michowich Y, et al. Re-duction of reinfarction and angina with use of low-molecular-weight heparin therapy after streptokinase (and heparin)in acute myocardial infarction. Am J Car-diol, 1990,77:1145
14 Cannon CP, McCabe CH, Henry TD, et al. Apilot trial of recombinant desulfatohirudin compared with hep-arin in conjunction with tissue-type plasminogen activa-tor and aspirin for acute myocardial infarction:Results of the Thrombolysis in Myocardial Infarction (TIM I) 5 trial. J Am Coll Cardiol, 1994,23:994
15 Lidon RM, Theroux P, Les perence J, et al. Api-lot, early an giogra phicpatency study usin gadirect thrombin inhibitor as adjunctive therapy to streptokinase in acute myocardial infarction. Cir, 1994,89:1567
16 Hjalmarson A, Herlitz J, Holberg S, et al. The Goteborg metoprolol trial. Effects on mortality and mor-bidity inacute my ocardial infarction. Cir, 1983, 67:Ⅰ 26
17 ISiS-1 Collaborative Group. Randomized trial of intravenous atenolol among 16027 cases of suspected my-ocardial infarction:ISIS-1.Lancet, 1986, Ⅱ:57
18 Yusuf S, Sleight P, Held P, et al. Routine medical management of acute my ocardial infarction.Lessons from overviews of recent randomized controlled trials.Cir, 1990,82(su pp l Ⅱ):Ⅱ 117
19 Yusuf S, Peto R, Lewis J, et al. Beta blockade during and after myocardial infartion:An overview of the randomized trial.Prog Cardiovasc Dis, 1985,27:335
20 Viscoli CM, Horwitz RI, Singer BH. Beta-block-ers after my ocardial infarction:influentce of first-year clinical course on long-term effectiveness. Ann Intern Med, 1993,118:99
21 Deedwania PC, Carbrajal EV. Secondary prevention after myocardial infarction. Too many choices, which ones work ?Arch Intern Med, 1993,153;285
22 “八五”国家攻关课题北京协作组. 急性心肌梗塞二级 预防-阿替洛尔和依那普利的效果. 中华心血管病杂志, 1996,24:183
23 Swedberg K, Held P, Kjekshus J, et al. Effects of the early administration of enalapril on mortality in pa-tients with acute my ocardial infarction. Results of the Cooperative New Scandinavian Enala pril Survival Study Ⅱ(CONSENSUS Ⅱ).NEng1 J Med, 1992,327:678
24 GISSI-3(Gruppo Italiano Per Lo Studio Della So-pravvivenza Nell'Infarto Miocardico). GISSI-3, Ef-fects of lisinopril and transdermal glyceryl trinitrate singly and to gether on 6-week mortality and ventricular function after acute my ocardial infarction. Lancet, 1994, 343:1115
25 ISIS Collaborative Group:ISIS-4 (Fourth Inter-national Study of Infarct Survival). A randomised trial comparing oral captopril versus placebo, oral mononitrate versus placebo, and intravenous mag nesium sulphate ver-sus control among 58043 patients with suspected acute my ocardial infartion. Lancet, 1995, 345:669
26 CCS-1 (Chinese Cardiac Study)Collaborative Group. Oral captopril versus placebo among 13634 pa-tients with suspected acute myocardial infarction:Interim report from the Chinese cardiac Study (CCS-1). Lancet, 1995,345:686
27 “八五”国家攻关课题上海协作组. 卡托普利治疗对急 性心肌梗塞二级预防的作用. 中华心血管病杂志, 1996, 24:187
28 中国 CEI-AMI 临床研究协作组. 卡托普利对前壁 与下壁心肌梗塞作用差异临床试验. 中华心血管病杂志, 1995, 23:165
29 Ambrosioni E, Borghi C, Magnani B. For the Sur-vival of Myocardial Infarction Long-term Evaluation (SM ILE) Study Investigators. The effect of the an-giotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior my ocardial infarc-tion. NEng l J Med, 1995, 332:80
30 The SOLVD Investigators. Effect of enalapril on mortality and the development of heart failure in asymp-tomatic patient with reduced left ventricular ejection fractions. NEngl J Med, 1992,327:685
31 Pfeffer MA, Braunwald E, Moye LA, et al. Effect of cap to pril on mortality and morbidity in patients with left ventricular dysfunction after my ocardial infarction. results of the Survival and Ventricular Enlargement (SAVE)Trial. NEngl J Med, 1992,327:669
32 The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators. Effect of rami pril on mortality and morbidity of survivors of acute my ocardial infarction with clinical evidence of heart failure. Lancet, 1993, 342:821
33 The TRACE Study Group. The Trandolapril Car-diac Evaluation (TRACE)study:rationale, design, and baseline characteristics of the screened population. Am J Cardiol, 1994, 73:44C
34 Syed M, Borzak S, Jafri SM. An giotensin-con-vertin genzyme inhibition after acute my ocardial infarc-tion with special reference to the Fourth International Study of Infarct Survival (ISIS-4).Prog Cardivasc Dis, 1996,39:201
35 Furberg CD, Psaty BM, Meyer JV. Nifedipine: Dose-related increase in mortality in patients with coro-nary heart disease. Cir, 1995, 92:1326
36 Wilcox RG, Hampton JR, Banks DC, et al. Trial of early nifedipine in acute myocardial infarction:The Trent Study. Br Med J, 1986, 293:1204
37 The Israeli SPRINT Study Group. Secondary pre-vention reinfarction Israeku bufeduoube truak (SORU BT), A randomized intervention trial of nifedip-ine in patients with acute myocardial infarction. Eur Heart J, 1988, 9:354
38 The Multicenter Diltiazem Postinfarction Trial Tesearch Group. The effect of diltiazem on mortalily and reinfarction after my ocardial infarction. N Engl J Med, 1988,319:385
39 Danish Study Group on Verapamil in Myocardial Infarction. Verapamil in acute myocardial infarction.Eur Heart J, 1984, 5:516
40 The danish Study Group on Verapamil in My ocar-dial Infarction. Effect of Verapamil on mortality and major events after actue my ocardial infarction (the Dan-ish Verapamil Infarction Trial-DAVIT-Ⅱ). Am J Cardiol, 1990, 66:779
41 Held PH, Yusuf S, Furberg CD. Calcium channel blocker in acute my ocardial infarction and unstable angi-na:an overview. Br Med J, 1989, 299:1187
42 Braun S, Boykov, Behar S, et al. Calcium antago-nists and mortality in patients with coronary artery dis-ease:a cohort study of 11575 patients. JACC, 1996,28:7
43 MacMahon S, Collins R, Peto R, et al. Effects of prophy lactic lidocaine in suspected acute my ocardial in-farction. An Overview of results from the randomized, controlled trials. JAM A, 1988,260:1910 44 Gheorghiade M, Goldstein S. Arrythmia suppres-sion in postmyocardial infarction patients with special notation to cardiac arrythmia suppression trial. Prog Cardiovasc Dis, 1991, 33;213
45 方儒修. 乙胺碘呋酮的艰辛历程. 心血管病学进展, 1996, 17:195
46 Cairns JA, Connolly ST, Roberts R, et al. For the Canadian Amiodarone M yocardial Infarction Arrhy thmia T rial Investigators. Randomised trial of outcome after myocardial infarction in patients with frequent or repeti-tive ventricular premature depolarisations:CAMIAT. Lancet, 1997, 349:675
47 Jullan DG, Camm AJ, Frangin G, et al. For the European Myocardial Infarct Amiodarone Trial Investiga-tors Randomised trial of effect of amiodarone on mortality in patients with left-ventricular dysfunction after recent my ocardial infarction:EMIAT. Lancet, 1997, 349:667
48 Held P, Teo KK, Yusuf S. Effects of beta-blocker, calcium channel blockers, nitrates, and magne-sium in acute myocardial infarction and unstable angina pectoris.In:Topol ES, ed. Interventional Cardiology, Philadelphia:Saunders, 1994:46
49 Ishikawa K, Kanamasa K, Ogawa I, et al. On be-half of the Secondary Prevention Group. Long-termni-trate treatment increases cardiac events in patients with healed myocardial infarction. Jpn Cir J, 1996, 60:9
50 周瑞海, 高海青. 调血脂药物应用进展. 现代诊断与 治疗, 1997, 8:118
51 Rackley CE. Monotherapy whit HMG-CoAreduc-tase inhibitors and secondary prevention in coronary artery disease. Clin Cardiol, 1996,19:683
52 Sacks FM, Pfeffer MA, Moye LA, et al. The ef-fect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. NEng l J Med, 1996, 335:1001
53 Faire UD, Ericsson CG, Grip L, et al. Secondary preventive potential of lipid-lowering drugs.The Bezafibrate Coronary Atherosclerosis Intervention Trial (BECA IL).Eur Heart J, 1996, 17(suppl):37
54 Malmberg K, Ryden L, Efendie S, et al. Ran-domized trial of insulin-g lucose infusion followed by subcutaneous insulin treatmetn in diabetic patients with acute myocardial infarction (DIGAM I study):effects on mortalily at one year. J Am Coll Cardiol, 1995,26:57
55 Teo KK, Yusuf S, Collins R, et al. Effects of in-travenous magnesium in suspected acute my ocardial in-farction:overview of randomized trials. Br Med J, 1991, 303:1499
56 Woods KL, FletcherS, Roffe C, et al. Intravenous magnesium sulphate in suspected acute myocardial infarc-tion:results of the second Leicester Intravenous Magne-sium Intervention Trial (LIM IT-2). Lancet, 1992, 339:1553
57 周瑞海, 高海青, 邹雄,等. 急性心肌梗塞患者血清维 生素 E 水平测定及其意义. 山东医科大学学报, 1991, 29: 234
58 Herbaczynska CK, Kosiewicz WB, Cedro K, et al. Supplementation with vitamin C and E suppresses leuko-cyteox ygen free radical procuction in patients with acute my ocardial infarction. Eur Heart J, 1995,16:1044
59 Miwa K, Miyagi Y, Igawa A, et al. Vitamin E deficiency in variant angina. Cir, 1996, 94:14
60 Hodis HN, Mack W, Labree L, et al. Serial coro-nary angio graphic evidence that antioxidant vitamin in-take reduces prog ression of coronary arery atherosclerosis. JAMA, 1995, 273:1849 |
